Case Presentation {#sec1_1}
=================

A 36 year-old woman with Her-2 negative metastatic gastric adenocarcinoma currently on capecitabine and oxaliplatin presented for oxaliplatin infusion. Laboratory testing one day prior showed a platelet count of 237 × 10^9^ and ahemoglobin of 10.9 g/dL with an MCV of 81.9 attributed to iron deficiency anemia, She had previously received 5-fluorouracil/leucovorin/oxaliplatin for 14 months and then was switched to single agent capecitabine for 2 months in the setting of stable disease. At progression of disease, oxaliplatin was added to capecitabine, which the patient had been on for the past 9 months.

Thirty minutes after the oxaliplatin infusion was started, the patient developed significant bleeding from her gums, epistaxis, and had 150 to 200 mL of bloody oral secretions. Laboratory testing showed a platelet count of \< 5 × 10^9^, white blood cell count of 2.6 × 10^9^, hemoglobin 6.2 g/dL, PT 16.4, INR 1.4, total bilirubin 0.5 mg/dL, LDH 211 U/L. Peripheral smear showed few platelets and no schistocytes. The patient was admitted and received intravenous immunoglobulin 1 g/kg, dexamethasone 40 mg IV for 4 days, and oral aminocaproic acid, with resolution of bleeding after one day. No platelet transfusions were given. She received 1 unit of packed red blood cells. The platelet count improved to 77 × 10^9^ after 4 days and normalized to 341 × 10^9^ one month later. Oxaliplatin was definitively discontinued.

Discussion {#sec1_2}
==========

Although myelosuppression is the most common cause of thrombocytopenia in cancer patients receiving oxaliplatin, there are several other recognized mechanisms of oxaliplatin-induced thrombocytopenia \[[@B1], [@B2], [@B3], [@B4], [@B5]\]. With myelosuppression, thrombocytopenia is usually asymptomatic and is accompanied by anemia and neutropenia \[[@B6]\]. Management includes observation and the occasional need for dose reductions or delays \[[@B7]\]. Oxaliplatin-induced ITP is a well-recognized but uncommon etiology of thrombocytopenia. The mechanism is platelet destruction mediated by oxaliplatin-dependent antibodies to platelet antigens, leading to a sudden drop in platelet count to \< 10 × 10^9^ and bleeding manifestations within several hours of oxaliplatin infusion. This typically occurs after \> 12 cycles of oxaliplatin and may be preceded by hypersensitivity reaction \[[@B7], [@B8]\]. Management includes platelet transfusion, corticosteroid therapy, and IV immunoglobulin therapy with resolution of thrombocytopenia within approximately 2 weeks. Definitive discontinuation of oxaliplatin is recommended \[[@B1], [@B9], [@B10]\].
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